Trial reportPediatric blood & cancer2025
Phase II Study of Responses to Vaccination in Pediatric Cancer Survivors Following Standard-of-Care Non-HSCT Chemotherapy.
Trial report in Pediatric blood & cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- PD-L1-Binding Antigen Presenters: Redirecting Vaccine-Induced Antibodies for Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
introductionSurvivors of childhood cancer exhibit variable humoral immunity to vaccine-preventable diseases (VPDs) following cancer treatment. An increasing number of children are surviving a cancer diagnosis, making it imperative to document the extent to which survivors are at risk for VPDs and their response to vaccinations.
methodsThis Phase II prospective study included 65 pediatric patients diagnosed with cancer and treated with intensive chemotherapy without transplantation. Serum vaccine antibody concentrations were determined for 12 VPDs: tetanus, diphtheria, pertussis, polio, Haemophilus influenzae, pneumococcus, hepatitis B, meningococcus A, measles, mumps, rubella, and varicella following completion of cancer treatment and after vaccination.
resultsMany patients lacked protective antibody levels to VPDs at the end of treatment. After vaccination, 87%-100% of patients had protective antibody titers against inactivated vaccines. The percentage of patients protected against the live attenuated vaccines was lower: measles (79%), mumps (83%), rubella (85%), and varicella (82%). Differences in response rates to vaccinations were not statistically significant for age (<7 vs. ≥7 years of age), diagnosis (hematologic disease vs. solid tumor), the time between the end of treatment and vaccination (3-6 vs. >6 months for inactivated vaccines), or between absolute lymphocyte count or CD4
conclusionFor pediatric cancer survivors, a single dose of inactivated vaccines given 3 months following the end of treatment protects against these VPDs without the need for assessment of serostatus after inoculation. For live attenuated vaccines, patients require two inoculations for protection, and we recommend an assessment of serostatus to inform patients and providers of their risk for acquiring one of these communicable VPDs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.